Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Island Pharmaceuticals Limited (ILA.AX)
Camberwell, VIC, AU
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes. The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach. Additionally, Island Pharmaceuticals has a research agreement with Compounds Australia, providing access to an extensive drug library containing roughly 4,500 molecules for potential drug repurposing and pipeline enhancement. In anticipation of its ISLA-101 Phase II clinical study, the company has also established a cooperative research and development pact with the U.S. Army. Other key agreements include a supply contract with Catalent for the production of Fenretinide softgels for individuals participating in dengue fever trials, and the entitlement to reference the National Cancer Institute's Investigational New Drug (IND) application for ISLA-101. The company, founded in 2017, is based in Camberwell, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.56% | -13.64% | +1.33% | +2.70% | -27.62% | -11.63% | +68.89% | +192.31% | +9.13% | -22.05% | -22.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-90.5% Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+28.7% Q4'25: -43.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+511.1%
-
EBIT margin Biotechnology: +0.0%-3,326.1%
-
ROIC Biotechnology: -16.1%— Q4'25: -6,837.7% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+92.0% Q4'25: +189.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×— Q4'25: 0.00× (vs Q4'23)
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
1.25M
est: 1.00M (+25.2%)
|
118.9K
est: 118.9K (+0.0%)
|
121.7K
121.7K – 121.7K
+2.4% YoY
|
480.80M
480.80M – 480.80M
+394,859.5% YoY
|
500.00M
500.00M – 500.00M
+4.0% YoY
|
| EBITDA |
-2.82M
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-2.86M
est: -200.0K (-1,331.9%)
|
-3.96M
est: -23.8K (-16,531.0%)
|
-24.3K
-24.3K – -24.3K
-2.4% YoY
|
-96.16M
-96.16M – -96.16M
-394,872.5% YoY
|
-100.00M
-100.00M – -100.00M
-4.0% YoY
|
| Net Income |
-2.86M
est: -4.88M (+41.3%)
|
-3.92M
est: -4.21M (+6.9%)
|
-3.07M
-3.07M – -3.07M
+27.1% YoY
|
-8.15M
-8.15M – -8.15M
-165.5% YoY
|
175.19M
175.19M – 175.19M
+2,250.2% YoY
|
| SGA |
1.85M
est: 37.13M (-95.0%)
|
2.67M
est: 4.42M (-39.6%)
|
4.52M
4.52M – 4.52M
+2.4% YoY
|
17.85B
17.85B – 17.85B
+394,859.5% YoY
|
18.57B
18.57B – 18.57B
+4.0% YoY
|
| EPS |
-0.03
est: -0.03 (-12.7%)
|
-0.02
est: -0.02 (+6.9%)
|
-0.02
-0.02 – -0.02
+27.1% YoY
|
-0.05
-0.05 – -0.05
-165.5% YoY
|
1.01
1.01 – 1.01
+2,250.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Charles Foster | MD, Chief Executive Officer, President & Executive Director | 369.8K | — |
| Cameron Jones | Chief Financial Officer & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ILA.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
